AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd

Link copied
Case Copied 78 min read

FEDERAL COURT OF AUSTRALIA

AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd [2020] FCA 672

File number: NSD 252 of 2019
Judge: GLEESON J
Date of judgment: 21 May 2020
Catchwords:

CONSUMER LAW – applicant seeking declaration that there is adequate scientific foundation for certain statements in advertisement for analgesic drug – where applicant previously contravened the Australian Consumer Law (Sch 2 to the Competition and Consumer Act 2010 (Cth)) and is permanently restrained from making certain representations – whether proceeding barred by doctrine of res judicata or subject to issue estoppel – whether new advertising materials convey restrained representation – whether adequate scientific foundation for new statements of superiority over certain other analgesics – application refused.

CONSUMER LAW – cross-claim – whether cross-respondent’s new advertisements for analgesic drug contravenes Australian Consumer Law – misleading or deceptive conduct – false or misleading representations – whether adequate scientific foundation for representation as to superiority of applicant’s analgesic over certain other analgesics – contraventions found

Legislation: Australian Consumer Law (Sch 2 to the Competition and Consumer Act 2010 (Cth)) ss 18, 29, 33
Cases cited:

Australian Competition and Consumer Commission v Coles Supermarkets Australia Pty Ltd [2014] FCA 634

Australian Competition and Consumer Commission v Harris Scarfe Australia Pty Ltd [2009] FCA 54

Australian Competition and Consumer Commission v Signature Security Group Pty Ltd [2003] FCA 3

Australian Competition and Consumer Commission v TPG Internet Pty Ltd [2013] HCA 54; (2013) 250 CLR 640

AFT Pharmaceuticals (AU) Pty Limited v Reckitt Benckiser (Australia) Pty Limited [2020] FCAFC 45

Blair v Curran [1939] HCA 23; (1939) 62 CLR 464

iNova Pharmaceuticals (Australia) Pty Ltd v Reckitt Benckiser (Australia) Pty Ltd [2018] FCA 1209

Jackson v Goldsmith [1950] HCA 22; (1950) 81 CLR 446

Medical Benefits Fund of Australia Ltd v Cassidy [2003] FCAFC 289; (2003) 135 FCR 1

National Exchange Pty Ltd v Australian Securities and Investments Commission [2004] FCAFC 90

Re Twenty-First Larena Pty Ltd; Maximova v Goodwin & Ors [2010] VSC 84

Reckitt Benckiser (Australia) Pty Limited v AFT Pharmaceuticals (AU) Pty Limited [2018] FCA 1552

Reckitt Benckiser (Australia) Pty Ltd v GlaxoSmithKline Australia Pty Ltd [2018] FCAFC 138

Tobacco Institute of Australia Ltd v Australian Federation of Consumer Organisations Inc [1992] FCA 630; (1992) 38 FCR 1

Tomlinson v Ramsey Food Processing Pty Ltd [2015] HCA 28; (2015) 256 CLR 507

Trade Practices Commission v QDSV Holdings Pty Ltd (t/as Bush Friends Australia) [1994] FCA 1562

Trawl Industries of Australia Pty Ltd v Effem Food Pty Ltd [1992] FCA 272

Date of hearing: 23-25 July 2019
Date of last submissions: 6 August 2019
Registry: New South Wales
Division: General Division
National Practice Area: Commercial and Corporations
Sub-area: Regulator and Consumer Protection
Category: Catchwords
Number of paragraphs: 202
Counsel for the Applicant/Cross-Respondent: P Crutchfield QC and L Merrick
Solicitor for the Applicant/Cross-Respondent: Corrs Chambers Westgarth
Counsel for the Respondent/Cross-Claimant: N Murray SC with A Vincent and J Edwards
Solicitor for the Respondent/Cross-Claimant:
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read AFT Pharmaceuticals (AU) Pty Ltd v Reckitt Benckiser (Austra... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2020] FCA 672
Decision Date

CaseChat Overview and Summary

AFT Pharmaceuticals (AU) Pty Ltd sought a declaration that there is an adequate scientific foundation for certain statements in its advertisement for the analgesic drug Maxigesic. Reckitt Benckiser (Australia) Pty Ltd, the cross-claimant, argued that the new advertising materials contravened the Australian Consumer Law as they conveyed a restrained representation and lacked an adequate scientific foundation. The case involved the interpretation of the Australian Consumer Law and the determination of whether the new advertising materials contravened the law.

The primary legal issue was whether there was an adequate scientific foundation for the claims made in the new advertisement, and whether the new advertising materials conveyed the restrained representation. This required an analysis of the scientific evidence provided by both parties and the interpretation of the relevant legal standards.

The Court found that the new advertisement and training aid did not convey a representation that Maxigesic provided faster onset and more meaningful pain relief than paracetamol and ibuprofen alone. The Court also found that the new advertising materials contravened the Australian Consumer Law as they conveyed the restrained representation and lacked an adequate scientific foundation. The Court considered the evidence provided by both parties and concluded that the new advertising materials did not have an adequate scientific foundation.

The Court refused the declaration sought by AFT Pharmaceuticals (AU) Pty Ltd and found that the new advertising materials contravened the Australian Consumer Law. The Court ordered that on or before 26 May 2020, the parties file and serve submissions in support of any application for non-publication of information contained in the reasons for judgment. Additionally, the parties were required to file and serve short minutes of orders to give effect to these reasons on or before 4 June 2020.

Orders

Orders of the court

1. On or before 26 May 2020, the parties file and serve submissions in support of any application for non-publication of information contained in the reasons for judgment.

2. On or before 4 June 2020, the parties file and serve short minutes of orders to give effect to these reasons.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Evidence

Evidence Before The Court

Accordingly, I do not accept that the new advertisement and the training aid convey a representation that Maxigesic provides faster onset and more meaningful pain relief than for paracetamol and ibuprofen alone.SCIENTIFIC EVIDENCEWitnesses AFT relied upon the expert evidence of Dr Russo and Professor Ronald Aaron Thisted, Professor Emeritus at the Department of Statistics and Public Health Sciences, University of Chicago. Reckitt relied upon the expert evidence of Professors Keech and Val Gebski, an expert biostatistician with a particular focus on the design of clinical trials. The witnesses prepared a helpful joint report and gave evidence concurrently. Neither party suggested that any adverse credit finding should be made about any witness, although AFT submitted that the approach of Professors Keech and Gebski “warrants caution”, because of their tendencies to raise no more than “potential doubts around the margins of the case”. My impression, particularly from the concurrent evidence, was that all of the experts gave their evidence with due independence, and endeavoured to provide relevant and impartial evidence, within their respective areas of expertise. Accordingly, I have not treated the evidence of Professors Keech and Gebski with any greater caution or scepticism than the evidence of the other experts. Daniels 2018 study The Daniels 2018 study was a clinical trial which compared:(a)a fixed dose combination of 975mg paracetamol/ 292.5mg ibuprofen (comprising three tablets) (that is, the Daniels FDC);(b)paracetamol;(c)ibuprofen; and(d)placebo. The study publication concludes (at p 1774) that the Daniels FDC:...provided significantly superior analgesia over equivalent monotherapy doses of either ingredient alone in the treatment of moderate to severe pain in the 48 hour period after the extraction of at least 2 impacted third molars. Compared with both monotherapies and placebo, the fixed-dose combination provided a significantly shorter onset of meaningful pain relief, reduced the consumption of opioid rescue medication, and reduced maximum pain scores... Under the heading “Discussion”, the study publication states:Acetaminophen and ibuprofen are well-known, commonly used, and well-established analgesic agents for the treatment of mild to moderate pain, and they target pain through separate pathways. The present study adds to the existing literature that shows the additive analgesic effect of combined acetaminophen and ibuprofen over either monotherapy after third molar removal, over ibuprofen monotherapy after root canal, and over acetaminophen monotherapy in other pain models. Several of pain studies in emergency department patients have not shown the superiority of combined therapy over monotherapy, possibly due to differences in study populations, baseline pain levels, indications, study duration, and dosing regiments. This study is the first to show the superiority of a fixed-dose combination that provides doses of both active ingredients at the recommended OTC levels and adheres to the FDA [US Food and Drug Administration] request for the dose of acetaminophen to be limited to 325mg per unit. This study reinforces previous research by showing that when co-administered, acetaminophen and ibuprofen combine to deliver a superior analgesic effect over either active ingredient alone. This study reinforces previous research by showing that when co-administered, acetaminophen and ibuprofen combine to deliver a superior analgesic effect over either active ingredient alone. With comparisons versus equivalent doses of each drug, it is evident that both active ingredients contribute to the superior analgesic effect of the fixed-dose combination.

Decision

Reasons for decision

The proceeding was commenced in February 2019, after a finding that AFT contravened the Australian Consumer Law, being Sch 2 to the Competition and Consumer Act 2010 (Cth), by publishing other different advertisements for Maxigesic: Reckitt Benckiser (Australia) Pty Limited v AFT Pharmaceuticals (AU) Pty Limited [2018] FCA 1552 (2018 judgment); decision upheld on appeal: AFT Pharmaceuticals (AU) Pty Limited v Reckitt Benckiser (Australia) Pty Limited [2020] FCAFC 45 (appeal judgment). The 2018 judgment was based on a conclusion that representations contained in those other advertisements lacked an adequate scientific foundation. The 2018 judgment did not consider the Daniels 2018 study. The 2018 judgment addressed claims which compared Maxigesic with paracetamol and ibuprofen as monotherapies (that is, in a product containing a single active ingredient, an example of which is an ibuprofen product marketed and sold by the respondent/cross-claimant (Reckitt) under the name “Nurofen”), as well as claims which compared Maxigesic with other combinations of paracetamol and ibuprofen (and, specifically, “Nuromol”, another product marketed and sold by Reckitt). The 2018 judgment principally concerned representations directed to comparative performance of the relevant drugs when taken at their respective maximum daily doses. The representations involving a comparison of Maxigesic with paracetamol and ibuprofen as monotherapies were:(1)when taken at their respective maximum recommended daily doses, Maxigesic provides stronger and more effective relief from pain than over the counter (OTC) doses of either paracetamol or ibuprofen alone (representation (3) in the 2018 judgment); and(2)Maxigesic reduces pain by at least 32% more than a full daily OTC dose of either paracetamol or ibuprofen alone throughout the period of administration of either drug (representation (4) in the 2018 judgment). By order 12 of orders made on 29 November 2018, the Court imposed a permanent injunction on AFT restraining it from making the representation (among others) that, when taken at their respective maximum recommended daily doses, Maxigesic provides stronger and more effective relief from pain than OTC doses of either paracetamol or ibuprofen alone without an adequate scientific foundation for doing so (restrained representation). Reckitt disputes AFT’s entitlement to the declaration sought on the basis that the claims made in the new advertisement do not have an adequate scientific foundation. Further, by its cross-claim, Reckitt alleges that the new advertisement conveys the restrained representation. Reckitt also contends that the new advertisement, and other advertising materials making similar representations, contravene the Australian Consumer Law because those representations lack an adequate scientific foundation. Accordingly, the principal issue for determination is whether or not there is an adequate scientific foundation for the claims now made and the representations conveyed by AFT’s advertising materials. ADVERTISING MATERIALS

Ratio Decidendi

Legal Principle Established